{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:59:51Z","timestamp":1789387191136,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"DOI":"10.1093\/jac\/dkx198","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T11:06:57Z","timestamp":1496228817000},"page":"2602-2606","source":"Crossref","is-referenced-by-count":17,"title":["Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii"],"prefix":"10.1093","volume":"72","author":[{"given":"Christine","family":"Robin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Patrick","family":"L\u00ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Melica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Massias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabah","family":"Redjoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihel","family":"Khoudour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Beckerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Maury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cordonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"key":"key\n\t\t\t\t20171012111929_dkx198-B1","author":"Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine association of the Infectious Diseases Society of America"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/bmt.2009.260","article-title":"Regionally limited or rare infections: prevention after hematopoietic cell transplantation","volume":"44","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B3","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00042560-199706010-00002","article-title":"Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients","volume":"15","year":"1997","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1086\/313509","article-title":"High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis","volume":"29","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B6","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archderm.1994.01690110049005","article-title":"Adverse cutaneous reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia","volume":"130","year":"1994","journal-title":"Arch Dermatol"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1128\/AAC.46.5.1163-1173.2002","article-title":"Antiparasitic agent atovaquone","volume":"46","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B8","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1592\/phco.19.13.1050.31598","article-title":"Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study","volume":"19","year":"1999","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2125.1994.tb04232.x","article-title":"Examination of some factors responsible for a food-induced increase in absorption of atovaquone","volume":"37","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B10","first-page":"176","article-title":"Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections","volume":"50","year":"1995","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B11","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJM199812243392604","article-title":"Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1086\/314893","article-title":"Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides","volume":"180","year":"1999","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B13","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1128\/AAC.40.9.2015","article-title":"In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii","volume":"40","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B14","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJM199305273282103","article-title":"Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS","volume":"328","year":"1993","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B15","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1056\/NEJM199111283252202","article-title":"A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tmaid.2014.12.010","article-title":"Failure of atovaquone-proguanil malaria chemoprophylaxis in a traveler to Ghana","volume":"13","year":"2015","journal-title":"Travel Med Infect Dis"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3201\/eid1402.070945","article-title":"Plasmodium falciparum malaria and atovaquone-proguanil treatment failure","volume":"14","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B18","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1086\/383150","article-title":"Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients","volume":"38","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B19","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1086\/314509","article-title":"Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure","volume":"178","year":"1998","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171012111929_dkx198-B20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/AAC.34.2.225","article-title":"Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis","volume":"34","year":"1990","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/9\/2602\/19540500\/dkx198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T08:52:47Z","timestamp":1569401567000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/72\/9\/2602\/3884449\/Plasma-concentrations-of-atovaquone-given-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,6,22]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx198","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9]]},"published":{"date-parts":[[2017,6,22]]}}}